Dr. Fidler on the Potential Utility of ctDNA to Inform Treatment Escalation in Lung Cancer

EP: 1.Mobocertinib Shows Encouraging ORR in EGFR Exon 20–Mutant Advanced NSCLC

Now Viewing

EP: 2.Dr. Fidler on the Potential Utility of ctDNA to Inform Treatment Escalation in Lung Cancer

EP: 3.Dr. Jänne on the Promise of Mobocertinib in EGFR Exon 20–Mutant NSCLC

EP: 4.Dr. Fidler on Balancing Benefit of Novel Agents in EGFR Exon 20–Mutant NSCLC With Toxicities

EP: 5.Dr. Brahmer on Emerging Targeted Therapies in EGFR Exon 20–Mutated Lung Cancer

EP: 6.Dr. Piotrowska on the Utility of Mobocertinib in EGFR Exon 20–Mutant NSCLC

EP: 7.Dr. Heymach on the Efficacy of Mobocertinib in EGFR Exon 20 Insertion–Mutated NSCLC

EP: 8.Dr. Goldberg on the Toxicity Profile of Amivantamab in Metastatic EGFR Exon 20–Mutant NSCLC

EP: 9.Dr. Spira on the Efficacy of Mobocertinib in Metastatic EGFR Exon 20–Mutated NSCLC

EP: 10.Dr. Borghaei on Unique Characteristics of EGFR Exon 20 Insertion Mutations in NSCLC

EP: 11.Heymach Homes in On Emerging Agents in EGFR Exon 20–Mutant NSCLC

EP: 12.Uncommon EGFR Mutations in Non–Small Cell Lung Cancer

Mary Jo J. Fidler, MD, associate professor, Department of Internal Medicine, Division of Hematology, Oncology and Cell Therapy, Rush Medical College, Rush University Medical Center, discusses the potential utility of circulating tumor DNA (ctDNA) to inform treatment escalation in lung cancer.

Biomarkers, such as ctDNA, could be utilized to tailor treatment intensification to patients with more aggressive disease, says Fidler. Once-a-day oral TKIs are more convenient for patients compared with oral TKIs plus intravenous antiangiogenic agents or cytotoxic chemotherapy, Fidler explains.

As such, ctDNA clearance could be used to inform which patients require treatment intensification and which patients can to remain on single-agent TKIs without disease progression, Fidler concludes.